Insulin receptor substrate 1 may play divergent roles in human colorectal cancer development and progression

Table 2 Analysis of correlations between Insulin receptor substrate 1, Bax and Bcl-xL expressions in primary colorectal cancer

Groups of patients			IRS-1–Bax			IRS-1–Bcl-xL
		n	P value	r	n	P value	r
All		123	< 0.001	0.513a	119	< 0.001	0.354a
Age (yr)	≤ 60	40	< 0.001	0.661a	41	0.001	0.481a
	> 60	81	< 0.001	0.424a	76	0.020	0.267a
Sex	Male	67	< 0.001	0.497a	63	0.011	0.319a
	Female	55	< 0.001	0.537a	55	0.002	0.415a
Localization	Rectum	54	< 0.001	0.460a	51	0.080	0.247a
	Colon	68	< 0.001	0.536a	67	< 0.001	0.446a
HP–type	A	101	< 0.001	0.535a	96	< 0.001	0.535a
	MA	22	0.953	-0.013	23	0.841	-0.044
G	G2	84	< 0.001	0.523a	83	0.006	0.300a
	G3	38	0.263	0.186	35	0.474	0.125
T	pT1 + pT2	10	0.455	0.268	11	0.005	0.772a
	pT3 + pT4	113	< 0.001	0.529a	108	0.001	0.302a
N	pN (-)	58	< 0.001	0.507a	57	0.007	0.351a
	pN (+)	65	< 0.001	0.493a	62	0.007	0.336a

Associations analyzed by Spearman's correlation rank test.

^aP < 0.05; n: Number of cases; r: Correlation coefficient; A: Adenocarcinoma; MA: Mucinous adenocarcinoma; G2: Moderately differentiated; G3: Poorly differentiated; N (-): Negative lymph node invasion; N (+): Positive lymph node invasion.